恶性肿瘤相关静脉血栓栓塞的机制和治疗进展  

Mechanism and treatment progress of cancer-related venous thromboembolism

作　　者：张贝贝 李振坤[2] ZHANG Beibei;LI Zhenkun(Wuhan Hospital of Traditional Chinese and Western Medicine,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430022,China;不详)

机构地区：[1]华中科技大学同济医学院附属武汉中西医结合医院,湖北武汉430022 [2]昆明医科大学第二附属医院呼吸与危重症医学科,云南昆明650000

出　　处：《中国临床研究》2025年第2期294-298,共5页Chinese Journal of Clinical Research

摘　　要：恶性肿瘤相关静脉血栓栓塞(VTE)是恶性肿瘤患者死亡的主要原因。癌细胞能够激活宿主细胞的凝血级联和其他血栓形成前特性,恶性肿瘤的治疗本身也是促进VTE的附加机制,这导致恶性肿瘤患者发生VTE的风险高于非恶性肿瘤患者。本文概述恶性肿瘤患者发生VTE的相关机制及其治疗方法。Cancer-related venous thromboembolism(VTE)is a major cause of death in cancer patients.Cancer cells can activate the host cell coagulation cascade and other pro-thrombotic characteristics.The treatment of cancer also serves as an additional mechanism that promotes VTE,leading to a higher risk of VTE in cancer patients compared to non-cancer patients.This article provides an overview of the relevant mechanisms and treatment methods for venous thromboembolism in cancer patients.

关 键 词：恶性肿瘤 静脉血栓栓塞 血栓形成 低分子肝素 口服抗凝药 腔静脉滤器 溶栓治疗 

分 类 号：R681.5[医药卫生—骨科学]